Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-054509
Filing Date
2026-02-17
Accepted
2026-02-17 15:57:28
Documents
81
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q neup-20251231.htm   iXBRL 10-Q 1818966
2 EX-31.1 neup-ex31_1.htm EX-31.1 19952
3 EX-31.2 neup-ex31_2.htm EX-31.2 20045
4 EX-32.1 neup-ex32_1.htm EX-32.1 10964
5 EX-32.2 neup-ex32_2.htm EX-32.2 12772
  Complete submission text file 0001193125-26-054509.txt   7353370

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT neup-20251231.xsd EX-101.SCH 999378
83 EXTRACTED XBRL INSTANCE DOCUMENT neup-20251231_htm.xml XML 1230777
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-41157 | Film No.: 26640520
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)